Benjamin Thinggaard

Medical doctor, resident in Ophthalmology
PhD student at the Research Unit of Ophthalmology, Odense University Hospital

[Young Retina Specialists @YoungRetina]

🔍 New Study Alert! 📚👁️

This nationwide study finds that the risk of post-injection endophthalmitis (PIE) is highest within the first three anti-VEGF injections, with a stable incidence rate of 0.022% over 16 years.

📅 December 2024 | DOI: 10.1111/aos.16727

#AntiVEGF

[Benjamin Thinggaard @Bthinggaard16]

Perhaps the latest published study ahead of #EURETINA24 in Barcelona?
👁️ We will be investigating patients with nAMD👁️

@VELUXFONDEN @SyddanskUni @OUHhospital @OUH_Eye @JakobGrauslund @YousifSubhi

[Ophthalmology Ther @Ophthal_Therapy]

The I-OPTA Questionnaire: A National Assessment of Patients with Neovascular Age-Related Macular Degeneration - https://t.co/rjJGeXNV6Q
#Ophthalmology

[Benjamin Thinggaard @Bthinggaard16]

Thanks for the collaboration, @JakobGrauslund @YousifSubhi @LonnyStokholm , Frederik Pedersen, Jimmi Wied, Ryo Kawasaki

@OUH_Eye @OUHhospital @SyddanskUni

[Benjamin Thinggaard @Bthinggaard16]

Thrilled to announce our new study on endophthalmitis after anti-VEGF injections! We found a consistently low incidence rate, with the highest risk in the first 3 injections. Great news for patients receiving this treatments!
https://t.co/E4NORFfHzI

[Benjamin Thinggaard @Bthinggaard16]

@JakobGrauslund @LonnyStokholm @YousifSubhi @tlsophtha @KatrineHartFred

[Benjamin Thinggaard @Bthinggaard16]

Great news for wet AMD patients receiving anti-VEGF injections! Our recently published study reveals no increased mortality risk. Previous studies had prompted questions on this matter. @AAOjournal @OUH_Eye @OUHhospital @SyddanskUni @ARVOinfo https://t.co/5ooyEJgZeL

[Benjamin Thinggaard @Bthinggaard16]

What a fantastic way to end 2023!
Our study on the challenges faced by wet AMD patients in their treatment journey is now published in @BMJ_Open
Wishing you all a Merry Christmas! 🎄✨
@OUH_Eye @JakobGrauslund @SyddanskUni @OUHhospital @VELUXFONDEN
https://t.co/KOcHv884RR

[Benjamin Thinggaard @Bthinggaard16]

4 weeks ago, our study revealing a 50% surge in the demand for intravitreal anti-VEGF injections within just five years was published in @JAMANetworkOpen . Overwhelmed by the +15 articles covering the study. Grateful to everyone involved for their efforts.

[Benjamin Thinggaard @Bthinggaard16]

Extremely proud to announce that our study has been published in JAMA OPEN NETWORK. This study is crucial, highlighting the importance of prioritizing our healthcare services to meet the demands in hospitals.

[JAMA Network Open @JAMANetworkOpen]

Intravitreal VEGF inhibitor injections in Danish patients has grown considerably, with >900k injections given to 56k patients (13.8 per 1000 citizens), 2007-2022, and an anticipated 50% increase by 2027. Age & conditions play a role. https://t.co/JTjkRW0jgn

[Benjamin Thinggaard @Bthinggaard16]

Velkommen på forsiden!
En stor ære at tale med Oftalmologisk Tidsskrift om vores studie. Det er der kommet en anbefalelsesværdig artikel ud af. Se: https://t.co/4gCIV3V6fu #dkpol #AMD

[Øjenforskning OUH @OUH_Eye]

Just published our research on the link between diabetic eye disease and severe lung disease. Our findings reveal a significantly elevated risk of lung disease among individuals with diabetes. Grateful for the invaluable contributions of our collaborators.

[Øjenforskning OUH @OUH_Eye]

@YoungRetina @Retina_Int @OUH_Eye @VELUXFONDEN @DRNyheder @tv2nyhederne @LonnyStokholm @ODIN_OUH @OUHhospital @Ugeskriftet @dagensmedicin @CaspaseMC @DDEA_Denmark @SDCOdense @koebenhavns_uni #scicomm #research #science #diabetes

[Øjenforskning OUH @OUH_Eye]

Join us for a delightful Brunsviger! (a beloved Funen tradition). Two more papers accepted last week, making it a total of 20 accepted in 2023 (speed: 1/8 days). Let's keep up the pace after enjoying some cake!

[Benjamin Thinggaard @Bthinggaard16]

Great pleasure to moderate an extremely exciting session on new drugs and new delivery forms for the treatment of AMD. #ARVO2023 #AMD #Ophthalmology #firsttimeever

[Benjamin Thinggaard @Bthinggaard16]

#dksuresh #Eye #eyeresearch #retina #AMD #amd #ouh @SyddanskUni @rsyddanmark @P4Fyn

[Benjamin Thinggaard @Bthinggaard16]

Yesterday, I had the great honor to present my study about decreased risk of all-cause mortality among patients with wet AMD at ARVO 2023, New Orleans. What a huge stage, what a big audience and what a great pleasure. Thanks to #ARVO2023 for giving me the opportunity. #speaker

[Benjamin Thinggaard @Bthinggaard16]

@ARVOinfo @VELUXFONDEN @YoungRetina @KolkoEye @HMSeye @OUHhospital @OUHTalks @OUH_Eye @ODIN_OUH @AAOjournal @JAMAOphth @aao_ophth @OTEurope @AJOphthalmology

[Ophthalmology @AAOjournal]

Vascular endothelial growth factor inhibition in retinal vein occlusion does not associate with cardiovascular morbidity and mortality https://t.co/U5qmECsyIH @KatrineHartFred @OUH_Eye

[Benjamin Thinggaard @Bthinggaard16]

A great honor to be part of this study about patients with blood clots in the eye. Soon, the next study about patients with wet AMD will be presented. Stay tuned!

[Øjenforskning OUH @OUH_Eye]

Population-based data on safety of vascular endothelial growth factor inhibitory treatment in retinal vein occlusion by @KatrineHartFred and colleagues is now available open access. Check it out at https://t.co/C0DLJCHfrK.
@YoungRetina @AAOjournal #rvo #vegfinhibitors

[Benjamin Thinggaard @Bthinggaard16]

Dejligt med gode samarbejdspartnere, som skriver om mit projekt, og dermed hjælper med at finde patienter stoppet i behandling for våd AMD, der kan indgå i studiet.
Tak til @fagligeseniorer

https://t.co/DMsj0WU5my